RUNX1/ETO-IN-1 

RUNX1/ETO-IN-1 is a RUNX1-ETO oncogenic fusion protein inhibitor that specifically targets the NHR2 oligomerization domain. RUNX1/ETO-IN-1 directly interacts with the NHR2 (K_D,app = 39 μM). RUNX1/ETO-IN-1 exhibits anti-leukemic activity by inducing apoptosis and promoting differentiation in RUNX1/ETO-translocated AML cells. RUNX1/ETO-IN-1 remains essentially uncharged at physiological pH, demonstrating superior membrane permeability^[1].

RUNX1/ETO-IN-1 (Cmpound M23) (96 h) Inhibits cell viability with an IC₅₀ of 62.14 µM in the AML cell line SKNO-1 carrying the t(8;21) translocation that results in RUNX1/ETO^[1].

RUNX1/ETO-IN-1 (20-200 µM) reduces the thermal stability of NHR2 (ΔTm = -1.6°C) in a concentration-dependent manner, likely by interfering with the tetramer-dimer equilibrium^[1].

RUNX1/ETO-IN-1 (50-100 µM, 24 h) arrests cell cycle and potential induction of apoptosis in SKNO-1 cells, but not in THP-1 cells^[1].

RUNX1/ETO-IN-1 (50-100 µM, 24 h) induces apoptosis in SKNO-1 cells by increasing caspase-3 and -7 activity but not in THP-1 and healthy NC-NC control cells^[1].

RUNX1/ETO-IN-1 (25-50 µM, 3 days) promotes differentiation in SKNO-1 cells by increasing CD11b expression, but not in K562 and THP-1 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

399.51

C₂₁H₂₅N₃O₃S

923865-06-9

CC1=CSC2=NC(CNC(C(C)C)C3=CC4=C(OCCCO4)C=C3)=CC(N12)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Gopalswamy M, et al. Identification of non-charged 7.44 analogs interacting with the NHR2 domain of RUNX1-ETO with improved antiproliferative effect in RUNX-ETO positive cells. Sci Rep. 2025 May 22;15(1):17720.  [Content Brief]